Form 4: Tempest Therapeutics CEO Granted Stock Options
Insider Transaction Report
Tempest Therapeutics CEO and President Matthew Angel was granted 269,621 employee stock options with an exercise price of $2.38, vesting over four years.
Summary
- Matthew Angel, CEO, President, Director, and 10% Owner of Tempest Therapeutics, Inc. (TPST), was granted 269,621 employee stock options.
- The options have an exercise price of $2.38 per share.
- The earliest transaction date for this grant was February 4, 2026.
- The options will vest with respect to 25% of the total shares on February 4, 2027, with the remaining shares vesting in 36 equal monthly installments thereafter.
- The expiration date for these options is February 3, 2036.
- Following this transaction, Matthew Angel beneficially owns 269,621 derivative securities directly.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive development, primarily due to the alignment of executive incentives with shareholder interests. It reflects a standard compensation practice and commitment to the company's future.
Positives
- The grant of employee stock options aligns the interests of CEO Matthew Angel with those of shareholders, incentivizing long-term company performance.
- The vesting schedule encourages continued service and commitment from a key executive.
Future Outlook
The vesting schedule for the granted options extends over four years, indicating an expectation of Matthew Angel's continued service and leadership at Tempest Therapeutics through at least February 2030.
Industry Context
StockSavvy.ai notes that the grant of stock options to a CEO is a standard practice in the biotechnology and pharmaceutical industries, aiming to retain key talent and align executive incentives with long-term shareholder value creation. Such grants are particularly common in growth-oriented companies like Tempest Therapeutics, where future success is heavily reliant on executive leadership and strategic execution.
Comparison to Industry Standards
- Executive compensation packages in the biotech sector frequently include significant equity components, such as stock options, to incentivize innovation and successful drug development. The size of this grant for Matthew Angel is within the typical range for a CEO of a company of Tempest Therapeutics' stage and market capitalization, comparable to grants seen at emerging biopharmaceutical firms like Mirati Therapeutics or Relay Therapeutics at similar points in their development cycles.
Stakeholder Impact
- Shareholders: The option grant aligns the CEO's financial interests with long-term stock performance, potentially benefiting shareholders if the company's value increases.
- Employees: The grant to the CEO may set a precedent or reflect a broader compensation philosophy that could impact other employees' equity incentives.
Next Steps
- The options will begin vesting on February 4, 2027, with subsequent monthly vesting installments over the following three years.
Key Dates
| Date | Description |
|---|---|
| 02/04/2026 | Date of earliest transaction (grant date of employee stock options). |
| 02/04/2027 | First vesting date for 25% of the granted stock options. |
| 02/03/2036 | Expiration date of the employee stock options. |
Keywords
Tempest Therapeutics, TPST, Matthew Angel, Stock Options, Executive Compensation, Insider Transaction, Form 4, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.